Phase II and III studies have confirmed the efficacy of topotecan as second-line treatment for SCLC. The management of patients with initial or relapsed SCLC, however, remains challenging.

Given that response and progression-free survival rates in each arm mirrored the respective overall survival results, it is unlikely that the differences are due to dissimilarities in second-line ...

Several studies are currently ongoing on tarlatamab both as monotherapy and in combination in earlier/second or later line setting in SCLC. The phase Ib DeLLphi-302 study is evaluating tarlatamab ...